SYK and Arthritis: The compound, CC-509, is a reversible, mixed ATP-competitive inhibitor of Syk that blocks FcR-dependent and FcR-independent cellular signaling, has favorable pharmacokinetic properties, and displays efficacy in two models of inflammation and arthritis.